Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 10/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | USP2 | O75604 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | CASP1 | P29466 | 8/20 | 0.41 |
| ▸ | CASP7 | P55210 | 8/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2402650 | 0.99 | ADRB1 (0.44) | ADRB1FLT3MEN1KMT2AALDH1A1 | |
| SCHEMBL2403073 | 0.87 | MET (0.46) | FLT3MEN1KMT2AALDH1A1USP2 | |
| SCHEMBL2401468 | 0.82 | ADRB1 (0.44) | ADRB1FLT3MEN1KMT2AALDH1A1 | |
| SCHEMBL2401936 | 0.82 | HTT (0.40) | MEN1KMT2AALDH1A1HPGDGLA | |
| SCHEMBL2405574 | 0.81 | HRH4 (0.46) | ADRB1FLT3MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2405585 | 0.81 | ADRB1 (0.43) | ADRB1FLT3MEN1KMT2AALDH1A1 | |
| SCHEMBL2404780 | 0.76 | GBA1 (0.49) | KDM4E | |
| SCHEMBL2404654 | 0.76 | ALDH1A1 (0.43) | ADRB1FLT3MEN1KMT2AALDH1A1 | |
| SCHEMBL2402272 | 0.72 | CHRNB2 (0.40) | ALDH1A1KDM4EHTR2C | |
| SCHEMBL2400859 | 0.69 | HRH4 (0.46) | MEN1KMT2AALDH1A1USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | ADRB1 569/4885FLT3 1548/4885MEN1 1013/4885 |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PTPN11, PPM1F, PTPRF | ADRB1 4603/4885FLT3 197/4885MEN1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.